201 related articles for article (PubMed ID: 36259470)
21. Characteristics of IgG subclasses and complement deposition in BP230-type bullous pemphigoid.
Zheng M; Ujiie H; Iwata H; Muramatsu K; Yoshimoto N; Ito T; Ujiie I; Shimizu S; Sato-Matsumura KC; Shimizu H
J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):595-600. PubMed ID: 30394605
[TBL] [Abstract][Full Text] [Related]
22. Levels of anti-BP180 NC16A IgE do not correlate with severity of disease in the early stages of bullous pemphigoid.
Bing L; Xiping Z; Li L; Jun P; Yi-Xia W; Min Y; Qing L; Qiu-Ning S; Hong-Zhong J; Ya-Gang Z
Arch Dermatol Res; 2015 Nov; 307(9):849-54. PubMed ID: 26404084
[TBL] [Abstract][Full Text] [Related]
23. Omalizumab as an alternative therapeutic tool in the treatment of bullous pemphigoid: A case report.
Vico-Alonso C; Calleja-Algarra A; Aragón-Miguel R; Sánchez-Velázquez A; Velasco-Tamariz V; Ortiz-Romero PL; Monsálvez-Honrubia V
Dermatol Ther; 2019 Mar; 32(2):e12829. PubMed ID: 30659716
[TBL] [Abstract][Full Text] [Related]
24. IgG antibodies against immunodominant C-terminal epitopes of BP230 do not induce skin blistering in mice.
Feldrihan V; Licarete E; Florea F; Cristea V; Popescu O; Sitaru C; Chiriac MT
Hum Immunol; 2014 Apr; 75(4):354-63. PubMed ID: 24468586
[TBL] [Abstract][Full Text] [Related]
25. Role of BP230 autoantibodies in bullous pemphigoid.
Shih YC; Wang B; Yuan H; Zheng J; Pan M
J Dermatol; 2020 Apr; 47(4):317-326. PubMed ID: 32048350
[TBL] [Abstract][Full Text] [Related]
26. [Bullous pemphigoid: diagnosis and therapy].
Kneisel A; Hertl M
Wien Med Wochenschr; 2014 Sep; 164(17-18):363-71. PubMed ID: 25077677
[TBL] [Abstract][Full Text] [Related]
27. Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patients.
Chebani R; Lombart F; Chaby G; Dadban A; Debarbieux S; Viguier MA; Ingen-Housz-Oro S; Pham-Ledard A; Bedane CR; Picard-Dahan C; Berthin C; Dereure O; Konstantinou MP; Castel M; Jouen F; Joly P; Seta V; Duvert-Lehembre S; Le Roux C; Quereux G; Sassolas B; Brenaut E; Sin C; Richard MA; Bérard F; Giusti D; Belmondo T; Gille T; Caux F; Prost-Squarcioni C; Grootenboer-Mignot S; Alexandre M;
Br J Dermatol; 2024 Jan; 190(2):258-265. PubMed ID: 37792727
[TBL] [Abstract][Full Text] [Related]
28. Role of IgE in bullous pemphigoid: a review and rationale for IgE directed therapies.
Messingham KN; Pietras TA; Fairley JA
G Ital Dermatol Venereol; 2012 Jun; 147(3):251-7. PubMed ID: 22648326
[TBL] [Abstract][Full Text] [Related]
29. IgE recognition of bullous pemphigoid (BP)180 and BP230 in BP patients and elderly individuals with pruritic dermatoses.
Fania L; Caldarola G; Müller R; Brandt O; Pellicano R; Feliciani C; Hertl M
Clin Immunol; 2012 Jun; 143(3):236-45. PubMed ID: 22534318
[TBL] [Abstract][Full Text] [Related]
30. Normal human skin is superior to monkey oesophagus substrate for detection of circulating BP180-NC16A-specific IgG antibodies in bullous pemphigoid.
Emtenani S; Yuan H; Lin C; Pan M; Hundt JE; Schmidt E; Komorowski L; Stanley JR; Hammers CM
Br J Dermatol; 2019 May; 180(5):1099-1106. PubMed ID: 30315657
[TBL] [Abstract][Full Text] [Related]
31. BP230 IgE autoantibodies in topical-steroid-resistant bullous pemphigoid.
Shih YC; Yuan H; Shen J; Zheng J; Pan M
J Dermatol; 2021 Sep; 48(9):1372-1380. PubMed ID: 34128260
[TBL] [Abstract][Full Text] [Related]
32. Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180.
Mai Y; Nishie W; Izumi K; Shimizu H
Front Immunol; 2019; 10():1224. PubMed ID: 31191560
[TBL] [Abstract][Full Text] [Related]
33. IgG from patients with bullous pemphigoid depletes cultured keratinocytes of the 180-kDa bullous pemphigoid antigen (type XVII collagen) and weakens cell attachment.
Iwata H; Kamio N; Aoyama Y; Yamamoto Y; Hirako Y; Owaribe K; Kitajima Y
J Invest Dermatol; 2009 Apr; 129(4):919-26. PubMed ID: 19177144
[TBL] [Abstract][Full Text] [Related]
34. IgE antibodies in sera from patients with bullous pemphigoid are autoantibodies preferentially directed against the 230-kDa epidermal antigen (BP230).
Ghohestani RF; Cozzani E; Delaporte E; Nicolas JF; Parodi A; Claudy A
J Clin Immunol; 1998 May; 18(3):202-9. PubMed ID: 9624579
[TBL] [Abstract][Full Text] [Related]
35. Advancements in Bullous Pemphigoid Treatment: A Comprehensive Pipeline Update.
Karakioulaki M; Eyerich K; Patsatsi A
Am J Clin Dermatol; 2024 Mar; 25(2):195-212. PubMed ID: 38157140
[TBL] [Abstract][Full Text] [Related]
36. Basement membrane zone IgE deposition is associated with bullous pemphigoid disease severity and treatment results.
Kamata A; Kurihara Y; Funakoshi T; Takahashi H; Kuroda K; Hachiya T; Amagai M; Yamagami J
Br J Dermatol; 2020 May; 182(5):1221-1227. PubMed ID: 31330562
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the combination of BP180-NC16a enzyme-linked immunosorbent assay and BP230 enzyme-linked immunosorbent assay in the diagnosis of bullous pemphigoid.
Yang B; Wang C; Chen S; Chen X; Lu X; Tian H; Yu M; Zhang D; Shi Z; Zhou G; Zhang F
Indian J Dermatol Venereol Leprol; 2012; 78(6):722-7. PubMed ID: 23075641
[TBL] [Abstract][Full Text] [Related]
38. Clinical and immunological profiles of anti-BP230-type bullous pemphigoid: Restriction of epitopes to the C-terminal domain of BP230, shown by novel ELISAs of BP230-domain specific recombinant proteins.
Hayakawa T; Teye K; Hachiya T; Uehara R; Hashiguchi M; Kawakami T; Li X; Tsuchisaka A; Ohara K; Sogame R; Koga H; Hamada T; Ohata C; Furumura M; Ishii N; Fukano H; Shimozato K; Hashimoto T
Eur J Dermatol; 2016 Apr; 26(2):155-63. PubMed ID: 27087683
[TBL] [Abstract][Full Text] [Related]
39. Biological predictors shared by dementia and bullous pemphigoid patients point out a cross-antigenicity between BP180/BP230 brain and skin isoforms.
Julio TA; Vernal S; Massaro JD; Silva MC; Donadi EA; Moriguti JC; Roselino AM
Immunol Res; 2018 Oct; 66(5):567-576. PubMed ID: 30220011
[TBL] [Abstract][Full Text] [Related]
40. IgG autoantibody reactivity against bullous pemphigoid (BP) 180 and BP230 in elderly patients with pruritic dermatoses.
Feliciani C; Caldarola G; Kneisel A; Podstawa E; Pfütze M; Pfützner W; Hertl M
Br J Dermatol; 2009 Aug; 161(2):306-12. PubMed ID: 19485996
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
